The global HER-2 negative breast cancer market represents carcinomas that lack overexpression of human epidermal growth factor receptor 2 (HER2). These types of breast cancers account for around 70% of all breast cancer cases. While chemotherapy and radiation have traditionally been used to treat HER-2 negative breast cancer, newer immunotherapies which activate the body's immune system to fight cancer cells are gaining popularity. Immunotherapies offer more targeted treatment with less severe side effects compared to traditional options.

The global HER-2 negative breast cancer Market is estimated to be valued at US$ 15982.51 Bn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

Immuno-oncology therapies represent a major opportunity in the Global HER-2 Negative Breast Cancer Market Size over the forecast period. Drugs such as checkpoint inhibitors which help immune cells recognize and attack cancer tumors are demonstrating strong potential. Key immunotherapies in clinical trials for HER-2 negative breast cancer include anti-PD-1/PD-L1 antibodies pembrolizumab and atezolizumab. By selectively enhancing the body's natural defenses, immunotherapies could significantly improve patient outcomes compared to traditional chemotherapies with fewer side effects. This advantages makes immuno-oncology an increasingly attractive treatment strategy and thus offers lucrative growth prospects.

Porter's Analysis

Threat of new entrants: Low as the HER2-negative breast cancer market is highly consolidated and requires high R&D investments and regulatory approvals.

Bargaining power of buyers: Moderate as many pharmaceutical companies provide treatment options but also collaborate with each other.

Bargaining power of suppliers: Low due to the availability of substitutes and less differentiation in products.

Threat of new substitutes: High as alternative treatment options are available and research is ongoing in targeted therapies.

Competitive rivalry: High due to the presence of major players and pipeline drugs.

SWOT Analysis

Strength: Effective treatment options with manageable side effects. Growing awareness levels regarding early detection and management.

Weakness: High cost of targeted therapies. Relapse risk after remission.

Opportunity: Untapped markets in developing countries. Personalized medicines based on biomarkers/ genetics.

Threats: Patent cliff of blockbuster drugs. Stringent regulations for drug approvals.

Get More Insights On This Topic: http://medicalinfoblogs.weebly.com/blog/her-2-negative-breast-cancer-therapeutics-market-growth-accelerated-by-rising-adoption-of-targeted-immunotherapy-drugs